Kornimate/medical-research-clean huggingface dataset:
circle dance for family caregivers of the elderly with alzheimer.

Conditions: Family Caregiver

Summary: the primary objective of this research is to compare the effects of a 12-week circlecare on physical functioning of family caregivers of the elderly with ad. effects on cognition, psychosocial and frailty-related aspects (secondary objective). the acute effect of one circle dance session on mood states (tertiary objective). this randomized controlled trial will involve 40 family caregivers over 50 years old allocated into a control group or an intervention group of 12-weeks (twice a week, 60 min per session) of circlecare. primary outcomes will include balance, speed of gait, lower limb muscle strength, functional mobility and risk of falls. secondary outcomes will include cognition, burden, stress, depression, quality of life and frailty. mood states will be a tertiary outcome. the effects of circlecare will be verified with an anova two-way test and a multiple comparison test when necessary. the analyzes will follow an intention-to-treat approach. the change in moods will be evaluated by the paired t-test. the level of significance will be set at p\<0.05. this study may guide professionals and health policymakers in deciding whether to implement this type of intervention. if positive effects are demonstrated, this program can be offered in public health services to other groups, given its low cost.


Eligibility criteria:
inclusion criteria: * 50 years or older. * family caregiver for at least 6 months of an elderly person with alzheimer's disease. * ability to walk without the help of another person. exclusion criteria: * cardiopulmonary or orthopaedic contraindication to the practice of physical exercise. * severe visual or hearing deficiency that impedes participation in the intervention and assessments.

Keywords: healthy aging family health exercise dance therapy
screening for abdominal aortic aneurysm in 65 year old males in oslo

Conditions: Abdominal Aortic Aneurysm

Summary: male subjects, 65 years of age, living in oslo, norway will be invited to be screened for abdominal aortic aneurysm.

the invited population will be offered ultrasound investigation of their abdominal aorta. further information regarding risk factors will be noted and measurement of ankle-brachial index will be measured/calculated. a further step in the future will be to sample blood with focus on different cytokines and genmediators.

Eligibility criteria:
inclusion criteria: * males aged 65 years exclusion criteria: * none

Keywords: abdominal aortic aneurysm, atherosclerosis
apparent diffusion coefficient as a prognostic biomarker in cervical cancer

Conditions: Cancer

Summary: this study aims to develop the technique of diffusion-weighted magnetic resonance imaging(dw-mri)for the assessment of stage 1 cervical cancers. an endovaginal receiver coil has been designed and developed at the institute of cancer research and royal marsden nhs foundation trust for use at high field strengths(3t). this will be used to evaluate if dw-mri at 3t can be used to differentiate different histological characteristics within whole tumours and so determine if the technique could be of prognostic value. the study hypothesis is that this technique will be able to differentiate tumours with histological features known to be associated with poor prognosis (tumour type, grade and lymphovascular space invasion).


Eligibility criteria:
inclusion criteria: * all patients with presumed early stage cervical cancer being considered for curative surgery exclusion criteria: * ferromagnetic metal implants * claustrophobia (mri incompatibility)

Keywords: magnetic resonance imaging
changes in the hypotalamic-pituitary region of patients with metabolic syndrome and obesity

Conditions: Overweight and Obesity; Metabolic Syndrome

Summary: this study aims to identify new morphological and quantitative magnetic imaging parameters of pituitary gland and sellar region in overweight and obese patient at baseline and after 3 years, dividing patients in 3 groups (weight loss through diet and lifestyle changes, weight loss through bariatric surgery, no weight loss)

this longitudinal prospective study in overweight and obese patients aims to identify and characterize new morphological and quantitative mri parameters of pituitary gland and sellar region assessed by texture analysis with a specific software (imagej©). these parameters will be correlated them to hypothalamic-pituitary-peripheral axis function, metabolism and body composition. data will be detected at baseline and at 3 years follow-up to quantitatively identify the different pituitary mri patterns in 3 groups: 1. patients without weight modifies 2. patients with weight loss obtain through diet and lifestyle changes 3. patients with weight loss obtained through bariatric surgery

Eligibility criteria:
inclusion criteria: * bmi \> 25 kg/m2 exclusion criteria: * malignant neoplasia; * current use of psychotropic drugs; * chronic renal failure; * pituitary macroadenomas and craniopharyngiomas; * contraindications to mri execution (p. e. pace-maker, metal foreign bodies like slivers, non mri compatible vascular clips or prosthesis)

Keywords: pituitary obesity overweight metabolic syndrome mri
comparative trial of iv lacosamide versus phenytoin for seizure management

Conditions: Seizures

Summary: the investigator plans to perform a prospective, randomized, single blinded, study that will compare patients treated with iv lacosamide to those treated with phenytoin in the intensive care unit (icu) setting. the investigator will also evaluate the rate of clinically evident and sub-clinical seizures, and to compare long-term outcomes between patients treated with lacosamide and those treated with phenytoin.


Eligibility criteria:
inclusion criteria: * traumatic brain injury (tbi) or subarachnoid hemorrhage (sah) * admitted to the hospital less than 48 hours prior to randomization * glasgow coma scale (gcs) score 3-8 (inclusive), or gcs motor score of five or less and abnormal ct scan showing intracranial pathology * hemodynamically stable * older than 18 years of age exclusion criteria: * no iv access * spinal cord injury * history of or ct confirmation of previous brain injury, including brain tumor, stroke, or a spontaneous intracerebral hemorrhage * hemodynamically unstable * suspected anoxia * liver failure * younger than 18 years of age * pregnant * allergy to phenytoin or lacosamide * inability to obtain consent

Keywords: lacosamide phenytoin
effects of spray and stretch on postneedling soreness and sensitivity after dry needling of a latent myofascial trigger point.

Conditions: Pain After Dry Needling

Summary: pain after dry needling or injection in the muscle is a frequent secondary effect in the treatment of myofascial pain syndrome. in this trial spray and stretch technique is evaluated as a method to reduce this soreness. as well, the characteristics and the different factors that influence in this pain will be described.


Eligibility criteria:
inclusion criteria: * subjects presenting latent trigger points in the trapezius muscle exclusion criteria: * subjects with active trigger points or absence of trigger points.
a study with cit-013 in hs patients

Conditions: Hidradenitis Suppurativa (HS)

Summary: the goal of this clinical trial is to learn if cit-013 works to treat hidradenitis suppurativa in adults. it will also learn about the safety of cit-013. the main questions it aims to answer are: does cit-013 lower the disease activity of hs patients? what medical problems do participants have when receiving cit-013? researchers will compare cit-013 to a placebo (a look-alike substance that contains no drug) to see if cit-013 works to treat the symptoms of hs. participants will: take receive 50 or 100 mg cit-013 or placebo every other week for 12 weeks visit the clinic once every 2 weeks for checkups and tests keep monitor their symptoms during this period


Eligibility criteria:
inclusion criteria: * male or female participants with hs of more than 6 months duration, * 18 years of age at screening visit, * hidradenitis suppurativa lesions present in ≥ 2 distinct anatomic areas, one of which is hurley stage ii or iii (according to hurley classification system), * a total abscess and inflammatory nodule (an) count of ≥ 5 at screening and day 1 prior to enrollment/randomization, * participant must have had an inadequate response to oral antibiotics or exhibited recurrence after discontinuation to, or demonstrated intolerance to, or have a contraindication to oral antibiotics for treatment of their hs, * total draining tunnel count less than 20 exclusion criteria: * any current and/or recurrent clinically significant skin condition in the treatment area other than hs, * prior treatment with a recombinant therapeutic protein during the 6 weeks before baseline * prior treatment with any of the following medications before baseline: 1. any other systemic therapy for hs (28 days before baseline) 2. any iv anti-infective therapy (14 days before baseline) * history of malignancy with exception of non-melanoma skin cancer that has been excised and cured,
safety and efficacy of topical idp-108 versus vehicle in patients with onychomycosis

Conditions: Onychomycosis

Summary: the purpose of this study is to evaluate the safety and efficacy of topical application of idp-108 versus vehicle in treating patients with onychomycosis.


Eligibility criteria:
inclusion criteria: * clinically diagnosed onychomycosis of the target nail * presence of mild to moderate onychomycosis, defined as 20 - 50% of the area of the target nail being clinically affected * has a positive koh examination from the target nail * has a positive dermatophyte culture from the target nail exclusion criteria: * presence of any disease or condition that might cause nail abnormalities or may interfere with the evaluation of the study drug * use of any systemic antifungal therapy within 4 weeks prior to the screening visit or non-responsive to systemic antifungal therapy for onychomycosis * use of any prescription or over-the-counter topical antifungal therapy for the toenails within 4 weeks prior to the screening visit * woman who is pregnant, nursing an infant, or planning a pregnancy during the study period
operant conditioning of the soleus stretch reflex in adults with cerebral palsy

Conditions: Cerebral Palsy; Spastic Cerebral Palsy

Summary: 12 adults with spastic cp will complete 6 baseline sessions and 24 down conditioning sessions held 3 times/week. all clinical and physiological assessments collected at baseline will be reassessed after study completion, and follow ups after 2 weeks, 1 month and 3 months. the soleus h reflex (electric analogue of the stretch reflex) will be elicited in all sessions. in each session, participants will complete 20 baseline trials and 225 down conditioning trials to decrease the magnitude of the h-reflex.

individuals with cp face significant challenges due to spasticity that causes activity and participation restrictions with increase in secondary conditions. this is caused by injury to the upper motor neurons causing disruption to the neural circuitry responsible for maintaining motor tone. a novel intervention, oc of the h reflex has shown promising effects to reduce spasticity and improve motor function in people with stroke and spinal cord. its many known benefits include easy administration, non-invasive technique, no side effects, and long-term retention. in the study, the investigators will attempt to decrease the increased muscle tone of individuals with cp. if successful, it will not only provide evidence for future clinical application but also broaden the scope for alternate or supplementary non-invasive treatment approaches to decrease spasticity.

Eligibility criteria:
inclusion criteria: 1. age 18 and above 2. diagnosis of spastic cerebral palsy 3. gross motor function classification system level i-iii 4. stable medical background 5. current medication will remain unchanged for 3 months 6. provides informed consent 7. can walk at least 10 meters with or without assistive device 8. meets minimum study procedure requirements (elicitation of h-reflex). exclusion criteria: 1. pregnancy 2. uncontrolled diabetes 3. weak dorsiflexion 4. history of cardiac conditions 5. cognitive deficits that interfere with study procedure and steps for completion 6. botox within 2 months of the study 7. h/o ankle surgeries in affected leg (dorsal root rhizotomy etc.) 8. regular use of electrical stimulation to lower extremity muscles 9. cochlear or metal implantations on body 10. no history of seizure after age 2 years 11. current use of antiseizure medicines 12. any metal or magnetic components in the head (surgical clips, metal work etc.) 13. implanted device or cardiac pacemakers (applicable for ds8r too) 14. skin disorders 15. damaged skin (wounds, broken skin, or recent scar tissue) 16. allergy to latex (tape)

Keywords: hoffman reflex spinal reflex conditioning
2-site safety study of besivance versus vigamox prophylactically in routine cataract surgery

Conditions: Corneal Health; Cataract Surgery

Summary: the purpose of this study is to demonstrate that besivance is equal to vigamox in safety and tolerance when used prophylactically in subjects undergoing routine cataract surgery.

subjects will be assigned to receive either besivance or vigamox (1:1) to be administered as 1 drop in the study eye 4 times daily starting 3 days prior to cataract surgery and continuing for 7 days post-operatively. sixty subjects (30 from ophthalmology consultants and 30 from ophthalmology associates) of any race and either sex, requiring cataract extraction with planned implantation of a posterior chamber intraocular lens.

Eligibility criteria:
inclusion criteria: * men or woen of any race, 18 years or older who have a cataract, and are planning to undergo cataract extraction by phacoemulsification with the implantation of a posterior chamber intraocular lens * study eye of patients who, in the opinion of the investigator, will experience improvement in visual acuity following surgery * patients who are able to understand and sign an informed consent form that has been approved by an irb exclusion criteria: * planned multiple procedures during cataract/iol implantation surgery. note: a planned limbal relaxing incision may be performed for the correction of astigmatism * use of topical ocular or systemic antibiotics within 14 days prior to surgery and through study exit * history of or fuch's corneal endothelial dystrophy * any ocular inflammation (aqueous cells or flare greater than grade 0) or ocular pain in the study eye that is present during the baseline visit. * recent (within 6 months) ocular trama to the operative eye (this includes intraocular surgery) * a history of chronic or recurrent inflammatory eye disease (eg, iritis, scleritis, uveitis, iridocyclitis, rubeosis iridis) in the operative eye * currently diagnosed uncontrolled glaucoma in the operative eye * congenital ocular anomaly (eg, aniridia, congenital cataract) in the operative eye * a visually nonfunctional fellow eye defined as a best corrected visual acuity \</= 35 etdrs letters (20/200 snellen equivalent) or worse * participation in any other investigational drug or device study within 30 days before cataract surgery * known or suspected allergy or hypersensitivity to any component of either test article * women of childbearing potential (those who are not surgically sterilized or post menopausal) may not participate in the study if any of the following conditions exist: 1. they are breast feeding 2. they have a positive urine pregnancy test at screening 3. they are not willing to undergo a urine pregnancy test upon entering or exiting the study 4. they intend to become pregnant during the duration of the study; or, 5. they do not agree to use adequate birth control methods for the duration of the study

Keywords: cornea ocular antibiotic cataract surgery
improvement of quality of life by cannabinoids in oncologic patients

Conditions: Medical Oncology; Palliative Care; Quality of Life; Cannabinoids

Summary: the goal is to explore whether the application of cannabis extract avextra 10/10 solution is suitable to contribute to an improvement in the symptom burden and well-being of oncological palliative care patients. the primary objective of the study is to demonstrate the improvement in global symptom burden in the intervention arm compared to the placebo control group over a period of 12±2 days, as measured by a percentage change in the value of the edmonton symptom assessment system total symptom distress score (esas tsds) at baseline and after 12±2 days.

170 oncological patients in palliative treatment will be randomized 1:1 to an thc:cbd-interventional arm and an placebo-arm. at the timepoints baseline, 12±2 days, 18±3 days, four weeks and eight weeks, the global burden of symptoms (esas tsds), quality of life (eortc qlq c15 pal) and other parameter will be measured and the intraindividual difference in comparison with the baseline will be compared between the groups. this study is intended to provide a significant contribution to evidence-based medicine (ebm) of cam in palliative medicine as well as for elderly and severely ill subjects (resp.) in general. the following gain of knowledge is expected: * substancial and reliable effects of cam in elderly subjects being in a multimorbid and psychologically very stressful situation of illness and life (resp.). * substancial and reliable effects of cam in aduld subjects being in a oncologically and palliative situation of illness and life (resp.). * compatibility of a cam-therapy in multimorbid patients with polypharmacotherapy. * importance of cam for the very frequent psychovegetative disturbance and comorbidities of many illnesses like sleepnesness, loss of appetite, nausea, fear and affective disturbance. * possible reduction of costs and improved economics through cam

Eligibility criteria:
inclusion criteria: * ≥25 years old and legally competent * palliative oncological therapy * ecog status 1, 2 or 3, incapacitated for work * esas tsds \> or equals 16 * nutritional risk screening \> or equals 3 * pain numerical rating scale \> or equals 4 * informed consent * for wocbp: * negative pregnancy test * reliable contraception (pearl index \< 1%) exclusion criteria: * nausea \> or equals grade 3 (ctcae) or vomiting \> or equals grade 2 (ctcae) in the preceding week * inability to understand and complete the questionnaires * cannabis use in the last 6 weeks * alcohol addiction * pregnancy/lactation * contraindications or intolerance to the study medication (esp. psychosis) * simultaneous participation in other clinical studies (sumulataneous participation in non-interventional studies (i.e. biomarker-studies, registries) is allowed, if the study-aim does not interfere with measures of the second study) * any other condition as judged by the investigator, e.g. non-compliance

Keywords: belcanto
the lacosamide's effect on calcitonin gene-related peptide in migraine patients

Conditions: Effect of Drug; Migraine Disorders

Summary: we assessed serum cgrp concentrations before and after treatment in two hundred episodic migraine patients according to the international classification of headache disorders 3rd edition, aged 10-55 years. we divided them into two groups first one received ibuprofen 200-400 mg as a treatment for acute migraine attacks and lacosamide 50 mg bid for 3 months, and the other group received only ibuprofen 200-400 mg as a treatment for acute migraine attacks.

two hundred episodic migraine patients, according to the international classification of headache disorders 3rd edition, aged 10-55 years with migraines. we divided them into two groups first one received ibuprofen 200-400 mg as a treatment for acute migraine attacks and lacosamide 50 mg bid for 3 months, and the other group received only ibuprofen 200-400 mg as a treatment for acute migraine attacks. our selected patients were naive and didn't receive any other prophylactic therapy for migraine. for each patient, the investigators did 1. detailed history taking with stress on age, sex, and criteria and type of migraine 2. general examination 3. full neurological examination: full neurological examination 4. laboratory investigations include: serum creatinine, liver functions test to exclude any metabolic disorder. 5. approximately 5 ml of venous blood was drawn from all participants and centrifuged at 1000×g for 10 min. serums were separated from the blood sample and stored at - 20 ℃. the serum calcitonin gene-related peptide (cgrp) concentrations will be measured by adapting the enzyme-linked immunosorbent assay (elisa) kit following manufacturer protocols. 6. serum level cgrp before starting treatment and after three months of treatment 7. mri t1, t2, and flair to exclude any secondary cause of headache.

Eligibility criteria:
inclusion criteria: * naive migraine patients according to the international classification of headache disorders 3rd edition aged 10-55 years, exclusion criteria: * patients with major neurological disorders such as ( epilepsy, ischemic or hemorrhagic stroke, multiple sclerosis, mitochondrial diseases, brain tumors, and patients with essential tremors. * patients with major systemic diseases such as malignancy, collagen diseases, liver diseases, and renal diseases. * patients with cardiovascular diseases like hypertension (systolic blood pressure of more than 130 and/or diastolic blood pressure of more than 85 mm/hg on at least three different occasions, diabetes (fasting plasma glucose level \>126 mg/dl and/or a casual plasma glucose \>200 mg/dl and/or hba1c more than 6.5. * patients with valvular and ischemic heart diseases, * patients who received prophylactic treatment for migraine, * patients with any contraindications to lacosamide.

Keywords: migraine lacosamide egypt
blood and tumor tissue samples from young patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is studying blood and tumor tissue samples from young patients with acute myeloid leukemia.

objectives: * to evaluate mer and axl expression in samples from pediatric patients with acute myeloid leukemia (aml). * to determine if abnormal expression of mer and axl is associated with poor clinical characteristics (e.g., induction failure or relapse) of aml in these patients. outline: this is a multicenter study. archived samples from pediatric patients with acute myeloid leukemia are analyzed for mer and axl expression by flow cytometry and western blot assays.

Eligibility criteria:
disease characteristics: * diagnosis of acute myeloid leukemia * children oncology group (cog) patient samples patient characteristics: * available clinical data prior concurrent therapy: * not specified

Keywords: childhood acute myeloid leukemia/other myeloid malignancies